Report Type : Therapy Reports
Report Category : Blood Diseases
Report Subcategory : Erythroblastosis Fetalis or Hemolytic Disease In Newborns
Price : 2999.00
Date : December 2021

Erythroblastosis Fetalis or Hemolytic Disease In Newborns : Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Erythroblastosis Fetalis or Hemolytic Disease In Newborns
Erythroblastosis fetalis is hemolytic anemia in the foetus (or infant, in the case of erythroblastosis neonatorum) caused by maternal antibodies being transmitted to foetal red blood cells through the placenta. Incompatibility between maternal and foetal blood groups, particularly Rho (D) antigens, is the most common cause of the illness.

Top 10 Companies:
Baxter International Inc
CSL Ltd
Kedrion SpA
Grifols SA
Octapharma AG
Emergent BioSolutions Inc
Nippon Chemiphar Co Ltd
Kamada Ltd
Momenta Pharmaceuticals Inc
Bharat Serums And Vaccines Ltd